There were 285 new cases of measles in the U.S. in 2024. Measles, also known as rubeola, is an infectious disease that is highly contagious and affects mostly children. Common symptoms of measles include fever, runny nose, sore throat, cough, and a rash. Although death rates from measles have decreased around the world, it is still responsible for around 81,000 deaths worldwide per year. Measles vaccination The main reason for the decrease in measles cases and deaths is due to high vaccination rates. The widely used MMR vaccine protects against measles, mumps, and rubella and is safe and effective. In 2023, around 91 percent of adolescents in the U.S. aged 13 to 17 years had received an MMR vaccination. However, in recent years there has been a rise in measles cases in many parts of the world due to vaccine hesitancy. Vaccine hesitancy Vaccine hesitancy refers to a refusal or reluctance to have children vaccinated, despite the overwhelming evidence that vaccines are safe and effective. This hesitancy comes from a misunderstanding of the ingredients in vaccines and how they work, a mistrust of doctors and pharmaceutical companies, and belief in the unfounded associations of vaccines with other diseases and disorders.

In 2023, there were a total of 58 cases of measles in the United States. Around 72 percent of measles cases that year were attributed to unvaccinated individuals. Meanwhile, those with two doses of vaccination only accounted for just three percent of cases. This statistic shows the number of measles cases reported in the United States from 2020 to 2024, by vaccination status.

In 1970, there were 22.79 new cases of measles per 100,000 population in the United States. However, this rate dropped to .08 in the year 2024. This statistic shows the number of new cases of measles per 100,000 population in the United States from 1919 to 2024.

The data shows the year wise distribution of number of Measles cases in children of age 0-5 years in different states of India. Note:-(1)Measles is an acute viral respiratory illness. It is characterized by a prodrome of fever (as high as 105°F) and malaise, cough, coryza, and conjunctivitis -the three pathognomonic enanthema (Koplik spots) followed by a maculopapular rash .

This statistic shows the number of infected persons with measles during the U.S. multi-state outbreak in 2014-2015. The outbreak was linked to a Californian amusement park. In the period between December 28, 2014, and April 10, 2015, 147 persons who became infected with measles were linked to this multi-state outbreak.

Multi-state measles outbreak in 2014-2015

In the United States there are currently 140 people affected by the recent measles outbreak, with the majority of cases in California. Between December 2014 and February 2015, there were also 7 cases in Arizona and 3 in Utah. Cases of measles in the United States are not unheard of, there were 116 cases in 2001 and up to 27,786 cases in 1990. Measles is a highly contagious infection which is characterized by fever, cough, and a red rash that spreads across the body within days of the initial symptoms. In extreme cases, measles can be fatal. The recent outbreak has been associated with a movement among some parents that are refusing to vaccinate their children. This movement prevents the achievement of herd immunity. Many of the people who have contracted the disease were unvaccinated. In a 2011 survey, 67 percent of individuals stated that parents who chose not to vaccinate their children were naïve.

The vaccination can prevent the disease and has decreased global mortality from the measles virus. Worldwide, about 94 percent of 1 year olds in the Americas are vaccinated against measles, compared to 78 percent in Southeast Asia. About 91.9 percent of children between the ages of 19 and 35 months have received the measles, mumps, and rubella (MMR) vaccination in the United States in 2013, up from a low of 86 percent in 1998.

In England and Wales, the number of measles cases peaked in 2012, when there were over 2,000 confirmed cases reported. In the first quarters of 2024, the number of confirmed cases of measles peaked again, reaching almost two thousand cases. This statistic displays the annual number of confirmed cases of measles in England and Wales between 2000 and 2024.

Project Tycho datasets contain case counts for reported disease conditions for countries around the world. The Project Tycho data curation team extracts these case counts from various reputable sources, typically from national or international health authorities, such as the US Centers for Disease Control or the World Health Organization. These original data sources include both open- and restricted-access sources. For restricted-access sources, the Project Tycho team has obtained permission for redistribution from data contributors. All datasets contain case count data that are identical to counts published in the original source and no counts have been modified in any way by the Project Tycho team. The Project Tycho team has pre-processed datasets by adding new variables, such as standard disease and location identifiers, that improve data interpretabilty. We also formatted the data into a standard data format. Each Project Tycho dataset contains case counts for a specific condition (e.g. measles) and for a specific country (e.g. The United States). Case counts are reported per time interval. In addition to case counts, datsets include information about these counts (attributes), such as the location, age group, subpopulation, diagnostic certainty, place of aquisition, and the source from which we extracted case counts. One dataset can include many series of case count time intervals, such as "US measles cases as reported by CDC", or "US measles cases reported by WHO", or "US measles cases that originated abroad", etc. Depending on the intended use of a dataset, we recommend a few data processing steps before analysis:

Analyze missing data: Project Tycho datasets do not inlcude time intervals for which no case count was reported (for many datasets, time series of case counts are incomplete, due to incompleteness of source documents) and users will need to add time intervals for which no count value is available. Project Tycho datasets do include time intervals for which a case count value of zero was reported. Separate cumulative from non-cumulative time interval series. Case count time series in Project Tycho datasets can be "cumulative" or "fixed-intervals". Cumulative case count time series consist of overlapping case count intervals starting on the same date, but ending on different dates. For example, each interval in a cumulative count time series can start on January 1st, but end on January 7th, 14th, 21st, etc. It is common practice among public health agencies to report cases for cumulative time intervals. Case count series with fixed time intervals consist of mutually exxclusive time intervals that all start and end on different dates and all have identical length (day, week, month, year). Given the different nature of these two types of case count data, we indicated this with an attribute for each count value, named "PartOfCumulativeCountSeries".

In 2022, there were three reported cases of measles in Canada, compared to over two thousand cases in 1995. This statistic shows the number of reported cases of measles in Canada from 1930 to 2022.

The nigerm folder includes

the data on reported measles cases and the yearly estimates of the population at district level in the subfolder "data"
the code used for the analysis presented as a R package.

The resolution of the weekly reported measles cases has been reduced. The data shared here are at the department level instead of the district level because the original data are not publicly available.

The package does not include the additional datasets already freely available. They remain available using the URLs provided in the manuscript.

New spikes of measles outbreaks in the European Economic Area (EEA) were reached in 2024, with over 5,200 cases of measles reported in March 2024, the highest monthly figure since June 2011. Recent increase in cases could be a result of the growing vaccine skepticism movement in some European countries.

In 1919, there were almost 13 deaths from measles per 100,000 population in the United States. However, this rate had dropped to zero by the year 2021. In early 2025, an outbreak of measles in Texas resulted in the death of a child. This was the first measles death in the United States since 2015. Measles is a highly contagious disease, that is especially dangerous for children. However, vaccines have significantly decreased the rate of cases and deaths in the United States.

Measles is a highly infectious, severe viral disease. The disease is targeted for global eradication; however, this result has proven challenging. In China, where countrywide vaccination coverage for the last decade has been above 95% (the threshold for measles elimination), measles continues to cause large epidemics. To diagnose factors contributing to the persistency of measles, here we develop a model-inference system to infer measles transmission dynamics in China. The model-inference system uses demographic and vaccination data for each year as model inputs to directly account for changing population dynamics (including births, deaths, migrations, and vaccination). In addition, it simultaneously estimates unobserved model variables and parameters based on incidence data. When fitted to yearly incidence data for the entire population, it is able to accurately estimate independent, out-of-sample age-specific incidence. Using this validated model-inference system, we are thus able to estimate epidemiological and demographical characteristics key to measles transmission during 1951–2004 for three key locations in China, including its capital Beijing. These characteristics include age-specific population susceptibility and incidence rates, the basic reproductive number (R0), reporting rate, population mixing intensity, and amplitude of seasonality. Key differences among the three sites reveal population and epidemiological characteristics crucial for understanding the current persistence of measles epidemics in China. We also discuss the implications our findings have for future elimination strategies.

Since 1980, the global number of measles cases has decreased dramatically. This statistic shows the number of cases of measles reported each year from 1980 to 2023 worldwide, by region.

MeaNS nomenclature of genotyped measles virus from Senegal and demographical characteristics of originated patients.

In the year 2018, 53,218 measles cases were recorded in Ukraine, versus 4,782 for the previous year. The statistic illustrates the countries with the highest increase in number of measles cases between the years 2017 and 2018. A UNICEF warning issued in March 2019 stated that cases of measles around the world were surging to 'alarmingly high levels'. The 10 countries in the statistics account for 74 percent of the global increase, which is a source of serious concern for public health professionals.

Dataset from the article Barello S, Nania T, Dellafiore F, Graffigna G, Caruso R. 'Vaccine hesitancy' among university students in Italy during the COVID-19 pandemic. Eur J Epidemiol. 2020 Aug;35(8):781-783. doi: 10.1007/s10654-020-00670-z. Epub 2020 Aug 6. PMID: 32761440; PMCID: PMC7409616.

Abstract

The debate around vaccines has been in the spotlight over the last few years in Europe, both within the scientific community and the general public debate. In this regard, the case of the Italian vaccination debate is particularly worrying given that Italy has been one of the European countries with the highest number of measles cases in the recent past. According to this scenario, we conducted a cross-sectional study on a convenience sample of Italian university students aimed at: (1) exploring their attitudes towards a future vaccine to prevent COVID-19 and; (2) evaluating the impact of the university curricula (healthcare vs. non-healthcare curricula) on the intention to vaccinate. Descriptive analysis on the 735 students that answered to the question on the intention to vaccinate showed that 633 (86.1%) students reported that they would choose to have a vaccination for the COVID-19 coronavirus; on the other side, 102 (13.9%) students reported that they would not or be not sure to vaccine (low intention to vaccinate). This means that in our sample more than one student out of 10 shows low intention to vaccinate (vaccine hesitancy). Furthermore, when running analysis comparing healthcare students versus non-healthcare students we found no significant differences in responses' percentage distribution (p = .097). Understanding the student's perspective about the future COVID-19 vaccine and supporting their health engagement and consciousness may be useful in planning adequate response and multidisciplinary educational strategies-including the psychological perspective on vaccine hesitancy underlying factors - in the post-pandemic period.

Survey responses on knowledge, attitudes, and practices about measles rapid diagnostic test (RDT) use at the end of the evaluation period, Malaysia, May-June 2020.

Contains data from World Health Organization's data portal covering the following indicators:
Infant mortality rate (probability of dying between birth and age 1 per 1000 live births), Adolescent birth rate (per 1000 women aged 15-19 years), Contraceptive prevalence (%), Unmet need for family planning (%), Under-five mortality rate (probability of dying by age 5 per 1000 live births), Median availability of selected generic medicines (%) - Public, Median consumer price ratio of selected generic medicines - Public, Children aged <5 years sleeping under insecticide-treated nets (%), Children aged <5 years with fever who received treatment with any antimalarial (%), Prevalence of condom use by adults during higher-risk sex (15-49) (%), Deaths due to tuberculosis among HIV-negative people (per 100 000 population), Incidence of tuberculosis (per 100 000 population per year), Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%), Prevalence of tuberculosis (per 100 000 population), Births attended by skilled health personnel (%), Maternal mortality ratio (per 100 000 live births), Children aged <5 years stunted (%), Cholera - number of reported cases, Diphtheria - number of reported cases, Japanese encephalitis - number of reported cases, Pertussis - number of reported cases, Number of new leprosy cases, Total tetanus - number of reported cases, Meningitis - number of reported cases, Malaria - number of reported confirmed cases, Poliomyelitis - number of reported cases, Yellow fever - number of reported cases, H5N1 influenza - number of reported cases, Plague - number of reported cases, Mumps - number of reported cases, Congenital Rubella Syndrome - number of reported cases, Neonatal tetanus - number of reported cases, Rubella - number of reported cases, Measles - number of reported cases, Life expectancy at birth (years), Neonatal mortality rate (per 1000 live births), Low-birth-weight newborns (%), Children aged <5 years overweight (%), Alcohol consumption among adults aged ≥ 15 years (litres of pure alcohol per person per year), Literacy rate among adults aged >= 15 years (%), Population (in thousands) total, Population median age (years), Population proportion under 15 (%), Population living on <$1 (PPP int. $) a day (%), Civil registration coverage of births (%), Population proportion over 60 (%), Gross national income per capita (PPP int. $), Total fertility rate (per woman), Population living in urban areas (%), Annual population growth rate (%), Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%), Median availability of selected generic medicines (%) - Private, Hospital beds (per 10 000 population), Private prepaid plans as a percentage of private expenditure on health, Per capita government expenditure on health at average exchange rate (US$), Per capita total expenditure on health (PPP int. $), Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%), Children aged <5 years with diarrhoea receiving ORT (%), Per capita government expenditure on health (PPP int. $), Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%), Antenatal care coverage - at least one visit (%), General government expenditure on health as a percentage of total government expenditure, Births by caesarean section (%), Median consumer price ratio of selected generic medicines - Private, Hepatitis B (HepB3) immunization coverage among 1-year-olds (%), External resources for health as a percentage of total expenditure on health, Number of dentistry personnel, Children aged 6-59 months who received vitamin A supplementation (%), Physicians density (per 10 000 population), Number of nursing and midwifery personnel, Neonates protected at birth against neonatal tetanus (PAB) (%), Hib (Hib3) immunization coverage among 1-year-olds (%), Social security expenditure on health as a percentage of general government expenditure on health, Number of physicians, [Deaths due to HIV/AIDS (per 100

The size of the Vaccine Contract Manufacturing Industry market was valued at USD 3.51 Million in 2023 and is projected to reach USD 7.37 Million by 2032, with an expected CAGR of 11.18% during the forecast period. Vaccine contract manufacturing is one of those specialized sectors that are manufacturing vaccines on behalf of other pharmaceutical companies. Several reasons push many firms into sourcing production at contract manufacturers: lower costs, increased capacity, and exploiting highly specialized expertise. In global healthcare systems, vaccine contract manufacturers play a highly significant role, especially in ensuring delivery in a timely and efficient manner in pandemic circumstances and more general public health emergencies. The process is very complex for vaccine contract manufacturing, ranging from production and culture of viral or bacterial antigens to purification, formulation, and filling into vials or syringes. The contract manufacturers must have highly set standards of quality and must meet all requirements given by the regulatory systems they use for manufacturing vaccines. The industry is very regulated since there are strict guidelines that ensure quality control and disinfection, which takes place through regular inspection. Vaccines are at the forefront in the prevention of infectious disease and in the protection of public health. They have undoubtedly been key in decreasing the cases of several diseases, including polio, measles, and smallpox. However, vaccine production does not take a lot of rocket science to perform. It is one of those tasks that require specialized facilities and equipment, as well as specialized expertise. Contract manufacturing has opened up the opportunity for pharmaceutical companies to focus on research and development and let the manufacturing process be left to experienced and reliable partners. Vaccine contract manufacturing has emerged as a critical practice in the last decade. The recent COVID-19 pandemic had leveraged the adoption of vaccine contract manufacturing. This was a race for the vaccines based on the development of COVID-19, and massive global effort included large pharmaceutical companies along with contract manufacturers who worked together towards addressing unprecedented levels of demand. Scaling up the manufacturing in the industry played a key role in curbing the spread of this virus and saving thousands of lives. Vaccine contract manufacturing is crucial not only in the management of pandemics but also in creating a solid safeguard for long-term availability of vaccines for a number of diseases. It helps pharmaceutical companies avoid reliance on a single manufacturing site that may be subject to interruptions, therefore giving less chance for break in supply chains. In addition, the factor is a critical component of vaccines supplied in developing countries where access to basic healthcare services can be really limited. Recent developments include: August 2022: Moderna inked an agreement with the Canadian government to construct a messenger RNA vaccine manufacturing factory in an undetermined location in Canada. According to the biotech firm, the partnership will give Canadians access to mRNA vaccines made in Canada against respiratory viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus., June 2022: Merck and Agilent Technologies collaborated with each other to advance process analytical technologies for downstream processing and overcome the gaps within downstream processing.. Key drivers for this market are: Advancements in Technology and Cost Benefits in Infrastructure and Operational Benefits, Increase in Initiatives Favoring Vaccinations; Favorable Patient Demographics and Growing Vaccinations of Newborns and Children. Potential restraints include: Rising High Costs of Vaccines, Lack of Storage Infrastructure and Limitations Associated with Supply Chain. Notable trends are: The Inactivated Vaccines Segment is Expected to Hold a Significant Share in the Vaccine Contract Manufacturing Market over the Forecast Period.

Although there has been an overall decline in a number of vaccine-preventable diseases in the U.S., the number of pertussis cases has increased since 1980. This statistic shows the number of reported cases of select vaccine-preventable diseases in the U.S. from 1980 to 2022.